文献速递其他结缔组织病

利妥昔单抗在抗合成酶抗体阳性与阴性特发性炎性肌病中的疗效与安全性:一项注册研究

Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

多个周期后分别为79%和67%。仅ARS-ab阳性组观察到显著的激素节约效应(P=0.001),最常见不良事件为感染。

要点

  • 仅ARS-ab阳性组观察到显著激素节约效应(P=0.001)。
  • 最常见不良事件为感染;ARS-ab阳性1例、阴性2例死亡。

核心结论

  • 无论自身抗体状态如何,接受多个利妥昔单抗周期治疗的多数患者可达中度/显著改善。
  • ARS-ab阳性患者还观察到显著的激素节约效应。

研究设计与样本

  • 基于瑞典风湿病质量登记注册的队列研究,纳入接受≥1个利妥昔单抗周期的成人特发性炎性肌病患者。
  • 疗效评估基于国际肌炎评估与临床研究(IMACS)核心指标集及2016年ACR/EULAR对PM和DM的改善定义。
  • 安全性评估包括研究期间药物相关不良事件和死亡。
  • 采用逻辑回归评估选定临床特征与一个利妥昔单抗周期后改善之间的关联。

主要发现

  • 多个周期后,ARS-ab阳性者中79%、ARS-ab阴性者中67%达中度/显著改善。
  • 仅在ARS-ab阳性组观察到显著激素节约效应(P=0.001)。
  • 最常见不良事件为感染;随访期间ARS-ab阳性1例、ARS-ab阴性2例死亡。

关键数值与推荐

  • 疗效改善采用2016年ACR/EULAR对PM和DM的改善定义(中度/显著改善)。
  • 多个周期后ARS-ab阳性者中度/显著改善比例为79%,阴性者为67%。
  • ARS-ab阳性组激素节约效应P=0.001。

临床怎么用

  • 对特发性炎性肌病患者,利妥昔单抗治疗多个周期可使多数患者获得中度/显著改善,无论ARS-ab状态。
  • ARS-ab阳性患者更可能获得激素节约效应,可据此考虑利妥昔单抗的激素替代作用。
  • 治疗期间需监测感染等不良事件。

局限性

  • 非随机对照设计,可能存在混杂因素。
  • 部分患者随访时间有限,长期安全性数据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Post-hoc analyses of the Rituximab in Myositis trial indicate that specific autoantibodies profiles may influence treatment response. We compared the efficacy and safety of rituximab in anti-synthetase antibody (ARS-ab) positive and negative patients. METHODS: Adult idiopathic inflammatory myopathy (IIM) subjects in the Swedish Rheumatology Quality Register who received ⩾ 1 cycle of rituximab were enrolled. Efficacy assessment was based on the International Myositis Assessment and Clinical Studies (IMACS) core set measures and the 2016 ACR/EULAR definition of improvement for PM and DM. Safety assessment included drug-related adverse event and death during study period. Comparisons were done within and between the ARS-ab defined groups before and after first and last cycles. Associations between selected clinical features and improvement after one rituximab cycle were assessed using logistic regression. RESULTS: Sixty-five subjects were included and 43 had a follow-up visit within 5-10 months. Seventy-eight percent of ARS-ab positive subjects had moderate/major ACR/EULAR improvement after one cycle compared with 50% in the ARS-ab negative group. After several cycles, 79% of the ARS-ab positive and 67% of the ARS-ab negative patients achieved moderate/major improvement. A significant glucocorticoid-sparing effect was only observed in the ARS-ab positive group (P = 0.001). The most frequent adverse events were infections. One ARS-ab positive and two ARS-ab negative patients died during follow-up period. CONCLUSION: Irrespectively of their autoantibody status, a majority of subjects treated with several rituximab cycles had moderate/major improvement. In addition, ARS-ab positive subjects experienced a significant glucocorticoid-sparing effect.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Leclair V, Galindo-Feria AS, Dastmalchi M, et al. Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study. Rheumatology (Oxford). 2019. PMID: 30690633. doi:10.1093/rheumatology/key450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。